Alvotech has struck an investment deal worth $45m that will give Yas Holding a 2.5% stake in the business, as well as rights to sell three Alvotech biosimilars in the MENA region.
Alvotech has struck a deal with United Arab Emirates-based “business development and investment group” Yas Holding that will give Yas a 2.5% stake in Alvotech, as well as exclusive rights to supply three of the firm’s biosimilar candidates in the Middle East and North Africa region.
“The total partnership value, including the purchase of new shares, an upfront license payment, along with subsequent milestone payments is...
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
